Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls.

ABSTRACT: Tafasitamab and lenalidomide were approved for second-line treatment of diffuse large B-cell lymphoma (DLBCL) based on a single-arm phase II study. This combination was superior to routine immunochemotherapy regimens when comparing matched observational cohorts. "Synthetic" control groups may support use of novel DLBCL therapies in the absence of randomized studies. See related article by Nowakowski et al., p. 4003.

SUBMITTER: Cherng HJ 

PROVIDER: S-EPMC9481674 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature